HOME >> BIOLOGY >> NEWS
Merck CEO Raymond Gilmartin to lecture at NJIT

Raymond V. Gilmartin, chairman, president and chief executive officer of Merck and Co., Inc., will visit New Jersey Institute of Technology (NJIT) on Feb. 23 to deliver a lecture titled "A Prescription for Change in U.S. Health Care."

As more and more Americans come to rely on prescription drugs to meet their health care needs, the pharmaceutical industry is receiving increasing attention from policy makers at every level. Gilmartin will discuss the ongoing challenges facing the U.S. pharmaceutical industry, with particular focus on the areas of access, affordability, innovation and quality of care.

Merck and Co., Inc. is one of the most respected and successful drug makers in the world. Headquartered in Whitehouse Station, Merck employs nearly 64,000 people worldwide. Merck's global sales were $22.9 billion in 2004.

Since the company was founded in 1891, Merck researchers have pioneered innovations for treating serious diseases a tradition that produced such major medical advances as penicillin, streptomycin and cortisone, among others.

Merck is also well known for its philanthropy. For nearly 20 years, Merck has donated a drug to treat river blindness in Africa and Latin America. The company responded to the recent tsunami disaster by pledging more than $10 million in aid and supplies. Nearer to home, Merck has contributed more than $20 million to the Merck Institute for Science Education, which partners with New Jersey and Pennsylvania school districts to improve science and math education.

Prior to joining Merck in 1994, Gilmartin was chairman, president and chief executive officer of Becton Dickinson. He received a bachelor's degree in electrical engineering from Union College in 1963 and an MBA from Harvard Business School in 1968. He serves on the boards of General Mills, Inc. and the Microsoft Corporation. He is chairman of the Board of Directors of The United Negro College Fund and is a trustee of the Healthcare Le
'"/>

Contact: Robert Florida
florida@njit.edu
973-596-5203
New Jersey Institute of Technology
16-Feb-2005


Page: 1 2

Related biology news :

1. Merck and AAAS announce 2007 winners of Outstanding Undergraduate Research Programs
2. Harvard Medical signs agreement with Merck to develop potential therapy for macular degeneration
3. Merck and AAAS announce 2006 winners for Outstanding Undergraduate Research Programs
4. Researchers gain support from Merck Sharp & Dohme for novel area of diabetes research
5. Nobel Laureate Sydney Brenner receives 2005 UCSD/Merck Life Science Achievement Award
6. Merck / AAAS announce 2005 winners for outstanding undergraduate research programs
7. Protein tyrosine phosphatases to be topic of ASBMB-Merck Award lecture
8. Award lectures for ASBMBs 2007 Annual Meeting
9. AACR establishes new lecture in honor of Princess Takamatsu
10. National Academies Advisory: March 5 lecture on ocean acidification
11. Becker to deliver plenary lecture at plasma science meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/15/2016)... Yissum Research Development Company of the ... the Hebrew University, announced today the formation of ... various human biological indicators. Neteera Technologies has completed its ... investors. ... electromagnetic emissions from sweat ducts, enables reliable and speedy ...
(Date:3/10/2016)... -- --> --> ... Access Management Market by Component (Provisioning, Directory Services, Password ... Size, by Deployment, by Vertical, and by Region - ... is estimated to grow from USD 7.20 Billion in ... Compound Annual Growth Rate (CAGR) of 12.2% during the ...
(Date:3/8/2016)... N.C. , March 8, 2016   ... sensor technology, today announced it has secured $11M ... by GII Tech, a new venture fund being ... with additional participation from existing investors TDF Ventures ... the funds to continue its triple-digit growth and ...
Breaking Biology News(10 mins):
(Date:5/6/2016)... AUSTIN, Texas , May 6, 2016 ... risk drug addiction from prescription pain medication when treating ... in adult stem cell therapy, doctors can go right ... potentially dangerous drugs. MedRebels, an educational organization, provides physician ... therapy and a search feature to find physicians across ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... on a definitive agreement to acquire Algynomics, a research-stage pain diagnostics company. The ... to identify individuals at increased risk for the development of chronic pain, which ...
(Date:5/5/2016)... ... May 05, 2016 , ... ProMIS ... of its first three targets, it has identified a fourth in a series ... in the development and progression of Alzheimer’s disease (AD). , “This ...
(Date:5/4/2016)... ... May 04, 2016 , ... Proove Biosciences, Inc. , the ... partnership with McGill University . The partnership is designed to advance research in ... to help patients in pain. With the new agreement, researchers at Proove Biosciences are ...
Breaking Biology Technology:
Cached News: